Finance Probe Blames Drug Makers, PBMs For Rising Insulin Prices

The Senate Finance Committee on Thursday (Jan. 14) released a bipartisan report that blames both drug companies and pharmaceutical benefit managers for rising insulin prices. Insulin is often singled out in the debate over drug prices. Prices for insulin products have doubled, and in some cases tripled, in the past decade, according to the Finance report. Insulin price increases are due in part to the fact that the biologic was until last year regulated as a drug. Generic drug makers...
Article Type: 
Site Name:
IDP Issue: 
Inside Drug Pricing - 01/18/2021
IDP Volume: 
Vol. 4, No. 3


Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.